Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Data from 2 phase 3, randomized, active-controlled,...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Taylor & Francis Group 2022-11-01
Sraith:Human Vaccines & Immunotherapeutics
Ábhair:
clinical trial
pneumococcal conjugate vaccine
streptococcus pneumoniae
20-valent
immunogenicity
at-risk
invasive pneumococcal disease
Rochtain ar líne:http://dx.doi.org/10.1080/21645515.2022.2126253

Ar líne

http://dx.doi.org/10.1080/21645515.2022.2126253

Míreanna comhchosúla